Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL563 (Ansaid, BTS 18,322, BTS-18322, Cebutid, Flubiprofen, Flurbiprofen, Froben, Froben sr, NSC-757037, Ocufen, Strefen, Transact, U-27,182, U-27182) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
Aldo-keto reductase family 1 member C1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5905] [UniProtKB: Q04828] | ||||||||
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C1 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 4 | pIC50 | >100000 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
Aldo-keto reductase family 1 member C2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5847] [UniProtKB: P52895] | ||||||||
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C2 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 4.49 | pIC50 | 32500 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
AKR1C3/Aldo-keto-reductase family 1 member C3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4681] [GtoPdb: 1382] [UniProtKB: P42330] | ||||||||
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C3 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 5.81 | pIC50 | 1560 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
Aldo-keto reductase family 1 member C4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4999] [UniProtKB: P17516] | ||||||||
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C4 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 4 | pIC50 | >100000 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
Fatty acid amide hydrolase/Anandamide amidohydrolase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3229] [GtoPdb: 1400] [UniProtKB: P97612] | ||||||||
ChEMBL | Inhibition of FAAH in Sprague-Dawley rat brain homogenates preincubated for 10 mins followed by addition of substrate measured after 30 mins by liquid scintillation counting | B | 4 | pIC50 | >100000 | nM | IC50 | Eur J Med Chem (2016) 109: 216-237 [PMID:26774927] |
COX-1 /Cyclooxygenase-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL221] [GtoPdb: 1375] [UniProtKB: P23219] | ||||||||
ChEMBL | Inhibition of COX-1 (unknown origin) | B | 5.7 | pIC50 | 1995.26 | nM | IC50 | Bioorg Med Chem (2017) 25: 316-326 [PMID:27842798] |
GtoPdb | - | - | 7.12 | pIC50 | 75 | nM | IC50 | Proc Natl Acad Sci USA (1999) 96: 7563-8 [PMID:10377455] |
ChEMBL | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | B | 7.68 | pIC50 | 21 | nM | IC50 | DrugMatrix in vitro pharmacology data |
ChEMBL | Inhibition of COX1 | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2007) 50: 1425-1441 [PMID:17341061] |
Cyclooxygenase-1 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2949] [UniProtKB: P05979] | ||||||||
ChEMBL | Binding affinity of compound towards prostaglandin G/H synthase 1 was evaluated | B | 6 | pKi | 1000 | nM | Ki | Bioorg Med Chem Lett (2004) 14: 667-671 [PMID:14741265] |
ChEMBL | Inhibition of ovine COX1 | B | 6.3 | pIC50 | 500 | nM | IC50 | Bioorg Med Chem (2010) 18: 2204-2218 [PMID:20188577] |
ChEMBL | Inhibition of ovine COX1 assessed as production of PGF2-alpha preincubated with compound followed by the addition of 5 uM arachidonic acid as substrate by enzyme immunoassay | B | 6.82 | pIC50 | 150 | nM | IC50 | Eur J Med Chem (2016) 109: 216-237 [PMID:26774927] |
ChEMBL | Reversible competitive inhibition of prostaglandin G/H synthase 1 | B | 7.92 | pIC50 | 12 | nM | IC50 | Bioorg Med Chem Lett (2004) 14: 667-671 [PMID:14741265] |
ChEMBL | In vitro inhibitory activity against Prostaglandin G/H synthase 1 in sheep | B | 7.96 | pIC50 | 11 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 307-312 [PMID:10091674] |
COX-1 /Cyclooxygenase-1 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4042] [GtoPdb: 1375] [UniProtKB: Q63921] | ||||||||
ChEMBL | Concentration required to inhibit cyclooxygenase-1 in rat blood | B | 6.77 | pIC50 | 170 | nM | IC50 | J Med Chem (2005) 48: 5705-5720 [PMID:16134939] |
COX-2 /Cyclooxygenase-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL230] [GtoPdb: 1376] [UniProtKB: P35354] | ||||||||
ChEMBL | Inhibition of COX-2 (unknown origin) | B | 5.7 | pIC50 | 1995.26 | nM | IC50 | Bioorg Med Chem (2017) 25: 316-326 [PMID:27842798] |
ChEMBL | Inhibition of recombinant human COX2 assessed as production of PGF2-alpha preincubated with compound followed by the addition of 5 uM arachidonic acid as substrate by enzyme immunoassay | B | 5.97 | pIC50 | 1060 | nM | IC50 | Eur J Med Chem (2016) 109: 216-237 [PMID:26774927] |
ChEMBL | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | B | 6.44 | pIC50 | 359 | nM | IC50 | DrugMatrix in vitro pharmacology data |
GtoPdb | - | - | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 307-12 [PMID:10091674] |
ChEMBL | In vitro inhibitory activity against Prostaglandin G/H synthase 2 (COX-2) in human | B | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 307-312 [PMID:10091674] |
ChEMBL | Inhibition of COX2 | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2007) 50: 1425-1441 [PMID:17341061] |
COX-2 /Cyclooxygenase-2 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4321] [GtoPdb: 1376] [UniProtKB: Q05769] | ||||||||
ChEMBL | Inhibition of mouse COX2 | B | 6.3 | pIC50 | 500 | nM | IC50 | Bioorg Med Chem (2010) 18: 2204-2218 [PMID:20188577] |
fatty acid binding protein 2/Fatty acid binding protein intestinal in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4879] [GtoPdb: 2532] [UniProtKB: P12104] | ||||||||
ChEMBL | Displacement of 1-anilinonaphthalene-8-sulphonic acid from I-FABP | B | 4.59 | pKi | 26000 | nM | Ki | J Med Chem (2008) 51: 3755-3764 [PMID:18533710] |
fatty acid binding protein 1/Fatty acid-binding protein, liver in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5738] [GtoPdb: 2531] [UniProtKB: P02692] | ||||||||
ChEMBL | Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay | B | 5.93 | pKi | 1180 | nM | Ki | J Med Chem (2008) 51: 3755-3764 [PMID:18533710] |
Organic anion transporter 1/Solute carrier family 22 member 6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1641347] [GtoPdb: 1025] [UniProtKB: Q4U2R8] | ||||||||
ChEMBL | TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells | F | 5.82 | pIC50 | 1500 | nM | IC50 | J Pharmacol Exp Ther (2000) 295: 10-15 [PMID:10991954] |
ASIC1 in Rat [GtoPdb: 684] [UniProtKB: P55926] | ||||||||
GtoPdb | - | - | 3.5 | pIC50 | 350000 | nM | IC50 | J Neurosci (2001) 21: 8026-33 [PMID:11588175] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]